Scotland says yes to Xeloda, Mepact, Tasigna and Prezista
11 August 2011
Francesca Bruce
Please Login to read the full article.
11 August 2011
Francesca Bruce
Please Login to read the full article.
RELATED CONTENT
NEWS
- Final 'yes' for Takeda's bone drug Mepact from NICE
- Patient access scheme prompts NICE U-turn on Novartis' Tasigna, while BMS will appeal against no for Sprycel
- Novartis trumps Bristol-Myers Squibb at NICE for chronic CML
- NICE stands by Novartis' cut-price Tasgina over BMS' Sprycel in second-line CML
ANALYSIS
Other Informa Analysis
COMMENT
Other Informa Comment
EVENTS
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
18 June 2012
Boston Convention & Exhibition Center, Boston, MA
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
